CHGCY (Chugai Pharmaceutical Co) E10: $0.53 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHGCY Chugai Pharmaceutical Co Ltd CHGCY
89 GF Score
Price $21.61
GF Value $24.68
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Chugai Pharmaceutical Co E10?

Chugai Pharmaceutical Co CHGCY -2.44% 89 E10 is $0.53 as of Jun. 2026. GuruFocus rates CHGCY with a GF Score™ of 89/100 and a GF Value™ of $24.68 (Modestly Undervalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Chugai Pharmaceutical Co's adjusted earnings per share data for the three months ended in Jun. 2026 was $0.220. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $0.53 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Chugai Pharmaceutical Co's average E10 Growth Rate was 18.60% per year. During the past 3 years, the average E10 Growth Rate was 20.60% per year. During the past 5 years, the average E10 Growth Rate was 25.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Chugai Pharmaceutical Co was 29.80% per year. The lowest was 16.20% per year. And the median was 24.95% per year.

As of today (2026-08-02), Chugai Pharmaceutical Co's current stock price is $21.61. Chugai Pharmaceutical Co's E10 for the quarter that ended in Jun. 2026 was $0.53. Chugai Pharmaceutical Co's Shiller PE Ratio of today is 40.77.

During the past 13 years, the highest Shiller PE Ratio of Chugai Pharmaceutical Co was 132.28. The lowest was 34.06. And the median was 55.80.


Chugai Pharmaceutical Co  (OTCPK:CHGCY) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Chugai Pharmaceutical Co's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=21.61/0.53
=40.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Chugai Pharmaceutical Co was 132.28. The lowest was 34.06. And the median was 55.80.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Chugai Pharmaceutical Co E10 Related Terms


Chugai Pharmaceutical Co E10 Historical Data

* Premium members only.

The historical data trend for Chugai Pharmaceutical Co's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chugai Pharmaceutical Co E10 Chart

Chugai Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.30 0.34 0.39 0.42 0.51

Chugai Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.50 0.52 0.51 0.53 0.53

CHGCY vs LLY, JNJ, ABBV: E10 Comparison

For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chugai Pharmaceutical Co Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Chugai Pharmaceutical Co's Shiller PE Ratio falls into.


CHGCY
89GF Score
Chugai Pharmaceutical Co Ltd CHGCY
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chugai Pharmaceutical Co E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Chugai Pharmaceutical Co's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.22/113.6000*113.6000
=0.220

Current CPI (Jun. 2026) = 113.6000.

Chugai Pharmaceutical Co Quarterly Data

per share eps CPI Adj_EPS
201609 0.035 98.000 0.041
201612 0.028 98.400 0.032
201703 0.050 98.100 0.058
201706 0.048 98.500 0.055
201709 0.058 98.800 0.067
201712 0.042 99.400 0.048
201803 0.080 99.200 0.092
201806 0.057 99.200 0.065
201809 0.059 99.900 0.067
201812 0.060 99.700 0.068
201903 0.096 99.700 0.109
201906 0.096 99.800 0.109
201909 0.136 100.100 0.154
201912 0.112 100.500 0.127
202003 0.145 100.300 0.164
202006 0.143 99.900 0.163
202009 0.173 99.900 0.197
202012 0.153 99.300 0.175
202103 0.133 99.900 0.151
202106 0.195 99.500 0.223
202109 0.237 100.100 0.269
202112 0.264 100.100 0.300
202203 0.338 101.100 0.380
202206 0.164 101.800 0.183
202209 0.144 103.100 0.159
202212 0.231 104.100 0.252
202303 0.167 104.400 0.182
202306 0.179 105.200 0.193
202309 0.159 106.200 0.170
202312 0.192 106.800 0.204
202403 0.151 107.200 0.160
202406 0.215 108.200 0.226
202409 0.233 108.900 0.243
202412 0.181 110.700 0.186
202503 0.198 111.100 0.202
202506 0.204 111.700 0.207
202509 0.229 112.000 0.232
202512 0.250 113.000 0.251
202603 0.221 112.700 0.223
202606 0.220 113.600 0.220

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $0.53 mean?
Chugai Pharmaceutical Co (CHGCY) has a E10 of $0.53 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Chugai Pharmaceutical Co and its competitors.
Is Chugai Pharmaceutical Co's E10 too high?
Chugai Pharmaceutical Co's current E10 is $0.53. Overall, Chugai Pharmaceutical Co has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chugai Pharmaceutical Co's E10 compare to LLY and JNJ?
Chugai Pharmaceutical Co's E10 of $0.53 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Chugai Pharmaceutical Co and its competitors. Chugai Pharmaceutical Co's current E10 is $0.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chugai Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co (CHGCY) is currently considered Modestly Undervalued. The stock's GF Value™ is $24.68, compared to a current price of $21.61 — trading 12.4% below its estimated fair value. The current E10 is $0.53. Chugai Pharmaceutical Co's overall GF Score™ is 89/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Chugai Pharmaceutical Co (CHGCY), the current E10 is $0.53 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chugai Pharmaceutical Co (CHGCY) Overvalued in 2026?

Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued. The current stock price of $21.61 is trading 12.4% below its estimated GF Value™ of $24.68. GuruFocus considers Chugai Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for CHGCY:

  • E10: $0.53
  • GF Value™: $24.68 vs. price of $21.61 (12.4% below fair value)
  • GF Score™: 89/100 with 1 warning sign

No single metric tells the full story. See the CHGCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Chugai Pharmaceutical Co Business Description

Address 2-1-1 Muromachi, Nihonbashi, 12th Floor, Nihonbashi Mitsui Tower, Chuo-ku, Tokyo, JPN, 103-8324
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
89GF Score

Get the complete analysis for CHGCY

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.61
Price
$24.68
GF Value